Adding immunotherapy to radiation for bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bladder cancer called high-grade T1 non-muscle invasive urothelial carcinoma that has come back after prior treatment or has high-risk features.
- You have had a recent surgery (TURBT) to remove visible tumors and confirm the cancer stage.
- You have not had radiation therapy to the pelvic area before.
- You have not had chemotherapy or immunotherapy for bladder cancer that goes through your whole body (prior treatment given directly into the bladder is okay).
- You are 18 or older, with good kidney, liver, and blood cell counts.
- You do not have active autoimmune disease, serious heart problems, or certain other cancers that are not under control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
This trial tests whether adding radiation therapy to immunotherapy after bladder removal surgery can help prevent cancer from coming back. It's for people with advanced bladder cancer who have already started immunotherapy.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
This trial tests a new type of radiation therapy that adjusts to your body's changes during treatment. It aims to reduce side effects and improve accuracy for people with bladder cancer.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
Hear when a new Non-Muscle Invasive Bladder Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.